Trial Profile
A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women Aged 18 to 40 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Streptococcal B vaccine conjugate (Primary) ; Streptococcal B vaccine conjugate
- Indications Streptococcal infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK; Novartis Vaccines
- 10 Mar 2020 Results published in the Vaccine
- 16 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Jul 2015 Planned End Date changed from 1 Oct 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.